Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Cancer has always been one of the leading causes of death in the world, and China is facing
more and more severe challenges from cancer. Among all the causes of cancer death, lung
cancer (25.2%) ranks first, among which non-small cell lung cancer (NSCLC) accounts for about
80% to 85%, of which about 1 / 3 of the patients have been in the local advanced stage (IIIA
stage / IIIB stage) at the time of initial diagnosis. For the patients with stage IIIA NSCLC
who can be operated on, surgery is still the most effective way to treat them. Even so, NSCLC
in stage I-III undergoing radical surgery is the most effective way 30-60% of the patients
eventually had relapse or distant metastasis. Therefore, people began to explore a new
treatment mode, preoperative neoadjuvant chemotherapy, to improve the survival rate of NSCLC
2.
At present, the NCCN guidelines for the new adjuvant treatment of NSCLC mainly recommend
platinum based dual drug chemotherapy.
Immunotherapy combined with chemotherapy will be a potential new adjuvant therapy in the
future, which can improve the resection rate of patients, reduce the recurrence rate after
surgery, and have tolerable adverse reactions.
Phase:
Phase 2
Details
Lead Sponsor:
First Hospital of Jilin University The First Hospital of Jilin University